News

Shares of Iovance Biotherapeutics (NASDAQ: IOVA) were up more than 17% late Tuesday afternoon after the clinical-stage biotech company announced that the Food and Drug Administration (FDA) had

AT&T (NYSE: T) stock is an alluring option for income investors thanks to its robust dividend, which at current share prices yields nearly 7%. Despite this -- and the company's position as one of

Investors looking for growth stocks that can make dramatic moves in a short time should look more closely at healthcare. Two stocks in this sector have already doubled this year and could climb much

Pfizer (NYSE: PFE) brought in enormous levels of revenue over the past couple of years thanks to its coronavirus vaccine and treatment. The company also continues to benefit from sales of

The healthcare industry is diverse and complex, with longtime staples and emerging disruptors to fit your portfolio -- and it also doesn't need to cost an arm and a leg. Plenty of stocks are trading

Price is sometimes an indicator of quality, whether on equity markets or elsewhere. But just because a stock has a low sticker price doesn't mean it isn't worth considering. Investors can find

The next 12 months could be dicey for the economy and the stock market, especially as the U.S. Federal Reserve recently predicted a recession could come by year-end. But even in this environment

With savvy stock-picking and a bit of patience, building wealth isn't as difficult as it is often made out to be. This is because quality businesses grow their revenue and profits, which makes their

In many cases, analysts are guilty of being overly optimistic about the near-term prospects of the stocks they cover. But sometimes they err in a completely opposite way.

Vertex Pharmaceuticals

If you're thinking of investing in Pfizer (NYSE: PFE) to generate some passive income from your portfolio, you won't need to spend very much to do so, provided that you're willing to play the long

You don't need much money to get started investing. And stocks with relatively low share prices have tremendous growth prospects.

Three Fool.com contributors identified no-brainer healthcare stocks

A blast of analyst price target cuts hit Medtronic (NYSE: MDT) stock on Friday, one trading session after the company published its latest set of quarterly earnings. Both the market and several

Analog Devices (NASDAQ: ADI) shareholders lost ground to the market this week. The stock dropped 10% through Thursday trading, according to data provided by S&P Global Market Intelligence. That's

For the last couple of years, the semiconductor industry has battled its share of challenges. From supply chain disruptions to chip shortages, companies like Nvidia (NASDAQ: NVDA) have seen better

Affordably priced shares -- typically seen as those trading under $30 on a per-share basis -- are a rarity among large companies with stable long-term growth prospects. That's because the market

Investors who watch AT&T (NYSE: T) closely know that it has spent the last two years atoning for a costly mistake. It not only strayed from its core service offerings but also overpaid to enter the

On the surface, Pfizer (NYSE: PFE) had some good news to report on Thursday. But investors viewed the positive as a negative, in light of its timing. This wasn't helped by an analyst's price-target

Image source: The Motley Fool.

Medtronic (NYSE: MDT)Q4 2023 Earnings CallMay 25, 2023, 8:00 a.m. ET

Ryan Weispfenning

Continue reading

Source Fool.com

Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. I'm talking about Novavax

Pfizer (NYSE: PFE) has been a losing play for investors over the past 12 months. To wit: The drugmaker's stock has fallen by a whopping 28.8% over this period. Part of that decline has been driven

Shares of the medical device maker Medtronic (NYSE: MDT) were down by 5% on heavy volume as of 10:53 a.m. ET Thursday. The big loss came after the company reported its 2023 fourth-quarter results

Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that